SL Science Holding Completes SPAC Merger, Begins Trading on Nasdaq Under 'SLBT'
SLBT sits 52% above its 52-week low of $3.59 on elevated volume (25× avg).
Summary
SL Science Holding Ltd. has completed its business combination and will begin trading on Nasdaq under the ticker 'SLBT', securing capital to advance its cellular therapy pipeline.
Key Events · M&A and Partnerships · SLBT
-
Business Combination Completed
SL BIO Ltd. and Horizon Space Acquisition II Corp. have finalized their business combination, forming SL Science Holding Limited.
-
Nasdaq Listing Commences
The combined entity, SL Science Holding Limited, will commence trading on the Nasdaq Global Market under the ticker 'SLBT' on June 15, 2026.
-
Strategic Capital Secured
The transaction, with an implied equity valuation of $5.568 billion for SL Bio, includes a $7.8 million PIPE financing to fund the development of Gamma delta T cell-based therapies.
-
Enhanced Leadership and Governance
The company has formalized an experienced corporate governance structure with a bolstered executive leadership and Board of Directors to support its public listing and growth strategy.
Analysis · SLBT · Life Sciences
This filing announces the successful completion of the business combination between SL BIO Ltd. and Horizon Space Acquisition II Corp., marking SL Science Holding's debut on the Nasdaq Global Market. The transaction, which implies an equity valuation of approximately $5.568 billion for SL Bio, includes a $7.8 million PIPE financing. This strategic move provides critical capital and access to U.S. institutional markets, enabling the company to accelerate the development of its Gamma delta T cell-based therapies for solid tumors and pursue global expansion.
At the time of this filing, SLBT was trading at $5.44 on NASDAQ in the Life Sciences sector. The 52-week trading range was $3.59 to $14.31. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.